Clinical Data, CombinatoRx in ATL313 deal

Clinical Data Inc. (NASDAQ:CLDA) granted CombinatoRx Inc. (NASDAQ:CRXX) exclusive, worldwide rights to ATL313 for use in a combination therapy to treat multiple myeloma (MM) and other B cell cancers. ...